Comparison Examination of efficacy and safety of new 5-ASA with Salazosulfapyridine preparation for ulcerative colitis.

Comparison Examination of efficacy and safety of new 5-ASA with Salazosulfapyridine preparation for ulcerative colitis. - The change of an effect and side effects to ulcerative colitis when it changes from Salazosulfapyridine to Asacol is evaluated.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006450

Enrollment

Registered

2011-10-01

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

The efficacy and the safety of the Asacol is examined by administering Asacol 2.4g/day switching from less than Pentasa 4g/day, and the medication of Asacol is continued for 8 weeks if at all possibl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Mild and moderate ulcerative colitis patients taking Salazosulfapyridine.

Exclusion criteria

Exclusion criteria: (1)Patients without agreement of this study (2)Pregnant women and women suspected of being pregnant (3)Patients with history of total or partial colectomy operation.

Design outcomes

Primary

Measure	Time frame
non-relapse rate by CAI score after two months	—

Countries

Japan

Contacts

Public ContactTomoyoshi Shibuya

Department of Internal Medicine,Juntendo University Department of Gastroenterology

tomoyosi@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026